Testing a nerve stimulation device for ALS motor neuron control

Plain-English translation of NCT06649955 on ClinicalTrials.gov ↗ · Source last updated January 2026 · Translation generated June 2026 · How we translate trials

This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.

What is this trial?

This trial is testing a device called MyoRegulator® that uses gentle electrical stimulation applied to the skin to calm overactive motor neurons (the nerve cells that ALS damages). Researchers believe this treatment may help slow ALS progression by reducing nerve cell hyperactivity and activating the body's natural cleanup processes for damaged proteins. The study will evaluate whether the treatment is safe, feasible to deliver, and shows early signs of helping people with ALS.

ALS damages motor neurons and causes them to become overactive, which accelerates disease progression and loss of muscle function. Animal studies show that this electrical stimulation treatment can slow disease progression and preserve motor neurons, but it has never been tested in people with ALS, so this trial aims to see if it is safe and tolerable in patients.

Do you qualify?

You likely qualify if…

you are between 18 and 80 years old
you have been diagnosed with ALS (sporadic or familial) within the last 3 years
your lung function is at least 50% of the predicted normal capacity
you are stable on current ALS medications (like Riluzole, Radicava, or Qualsody) for at least 30 days before starting the study
you have an ALS Functional Rating Score of 35 or higher, meaning you still have meaningful motor function

You likely don't qualify if…

you are on permanent assisted ventilation (more than 22 hours per day for more than 7 consecutive days)
you have only bulbar ALS (affecting only speech and swallowing)
you have an implanted pacemaker, cardiac device, brain stimulator, or other electrically or magnetically activated implant
you have had seizures or unexplained loss of consciousness in the past 12 months
you have damaged or broken skin at the areas where the electrodes would be placed

What participation looks like

You would receive the MyoRegulator® treatment three times per week for 4 weeks at the study site. Each session involves placing electrodes on your skin to deliver gentle electrical stimulation—a non-invasive procedure with no injections or surgery. After the 4-week treatment period, you would return for follow-up visits at 1 week, 1 month, and 3 months after your last treatment, with an optional visit at 6 months. The study team will monitor you for any side effects and measure your motor function and safety throughout.

AI-generated summary from trial data · Jun 1, 2026 · Not medical advice

Trial locations(1 site)

United States

Beth Israel Deaconess Medical Center, Boston, Massachusetts